Scope Fluidics has launched a manufacturing line for PCR system chips

Scope Fluidics – a biotechnological company listed on NewConnect, owner of innovative medical diagnostics projects – has launched its own semi-automatic manufacturing line in Warsaw, which allows for independent production of chips. The manufacturing infrastructure is also capable of assembling PCR|ONE analyzers. This event is a part of the implementation of the milestone associated with the execution of pre-registration tests.

Read More
The PCR|ONE system developed by Scope Fluidics achieves standard market parameters –the outcome of the second round of research in ALAB laboratories is now available

Curiosity Diagnostics – a member of the Scope Fluidics S.A. Capital Group – successfully completed the second series of pre-validation tests of the PCR|ONE system in ALAB laboratories. The results of the tests confirmed that the clinical parameters of bacteria detection s in compliance with the market standards and clinical requirements. The tests also proved the competitive advantage of the PCR|ONE system, i.e. a unique combination of time-efficiency and comprehensive character of the test for the presence of Staphylococcus aureus.

Read More
Scope Fluidics patents the key solution of the PCR|ONE system in the European Patent Office

Curiosity Diagnostics – a company that belongs to the Scope Fluidics S.A. Capital Group – has announced that it has obtained a conditional decision from the European Patent Office on granting the patent for the patent application titled „Device for simultaneous and uniform thermal cycling of samples and uses thereof”.

Read More
Scope Fluidics has completed the fourth stage of the PCR|ONE system – the panel for detecting Staphylococcus aureus is ready for testing in ALAB laboratoria

Curiosity Diagnostics, a company belonging to the Scope Fluidics S.A. Capital Group, has completed the fourth stage of R&D works on the PCR|ONE system for automatic analysis of the genetic material of the bacterial and viral pathogens, unmatched on account of the speed and comprehensiveness of testing.

Read More
Two Scope Fluidics projects among the most ground-breaking diagnostic products in the American Association for Clinical Chemistry competition

PCR|ONE and BacterOMIC, two innovative medical diagnostic systems developed by Scope Fluidics, a biotechnology company listed on NewConnect, are among the seven breakthrough medical solutions from around the world competing for the Disruptive Technology Award 2019 granted by the American Association for Clinical Chemistry (AACC), the world’s largest organization which brings together medical diagnostic specialists.

Read More